75 citations
,
November 1996 in “Fertility and Sterility” This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.
728 citations
,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 
50 citations
,
July 1996 in “Fertility and Sterility” This study found that finasteride significantly reduced hirsutism scores in women with idiopathic hirsutism and PCOS, despite no changes in serum androgen levels.
70 citations
,
August 1995 in “Fertility and Sterility” In this study, women with idiopathic hirsutism who took finasteride for 9 months experienced a significant reduction in hirsutism scores compared to those receiving a placebo, with minimal side effects.
34 citations
,
January 1995 in “The Journal of Clinical Endocrinology and Metabolism” 17 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride may effectively reduce hirsutism in women with idiopathic hirsutism, as evidenced by lower Ferriman-Gallwey scores and hormone levels, without significant adverse effects.
61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” 
21 citations
,
August 1994 in “Clinical endocrinology” This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.
187 citations
,
January 1994 in “The New England Journal of Medicine” Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
48 citations
,
November 1992 in “Clinical Endocrinology” Long-term finasteride use doesn't change bone density or metabolism.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.
